Rational basis for Trk inhibition therapy for prostate cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Prostate cancer cells survive without androgenic stimulation by activating specific pathways.
• The neurotrophin/trk signaling axis is implicated in the survival of non-androgen-dependent prostate cancer cells.
• Understanding these unique survival mechanisms is crucial for developing effective therapies.

Purpose of the Study:

• To document changes in neurotrophin and cognate receptor expression during prostate cancer progression.
• To investigate the role of the neurotrophin/trk axis in prostate cancer cell survival.
• To evaluate the efficacy of inhibiting trk signaling pathways in prostate cancer treatment.

Main Methods:

• Immunocytochemistry, RT-PCR, and ELISA were used to analyze neurotrophin ligands (NGF, BDNF, NT-3) and receptors (trk A, B, C, p75NTR) in normal and malignant prostate tissues.
• CEP-751, a trk signaling inhibitor, was employed to study its effects on prostate cancer cell lines.
• In vitro clonogenic survival assays were performed to assess the impact of CEP-751 treatment.

Main Results:

• Normal prostate stromal cells produce NGF, while epithelial cells express trk A and p75NTR but do not rely on this axis for survival.
• Malignant prostate cells secrete neurotrophins (NGF, BDNF, NT-3) and express trk A, B, and/or C receptors, losing p75NTR expression.
• CEP-751 treatment induced apoptotic death in malignant prostate cancer cells by inhibiting autocrine trk signaling.

Conclusions:

• Prostate carcinogenesis involves altered neurotrophin production and aberrant expression of trk receptors (A, B, C) with loss of p75NTR.
• Malignant prostate cells acquire a dependence on trk signaling pathways for survival.
• trk inhibition represents a promising and rational therapeutic strategy for prostate cancer.